The University of Virginia, Department of Diabetes Technology, seeks adults between the ages of 18-70 who have Type 1 Diabetes to participate in a clinical study. The purpose of this study is to test a Web-Based Information Tool (WIT). This software will provide additional information regarding your hypoglycemic risk, your hyperglycemia risks, your daily glycemic profile, and may suggest potential changes to your insulin parameters. You will continue to use your Tandem insulin pump with Control-IQ Technology, and you will be trained how to use and interact with WIT.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have advanced or metastatic Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that has become resistant to platinum-based therapy. Eligible participants enrolled in this study will be randomly assigned to 1 of 4 available treatments.

• Arm 1: Nemvaleukin in combination with pembrolizumab
• Arm 2: Pembrolizumab monotherapy
• Arm 3: Nemvaleukin monotherapy
• Arm 4: Investigator’s choice chemotherapy

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have Metastatic Castration-Resistant Prostate Cancer (mCRPC). The purpose of this study is to assess the safety and tolerability (good and bad effects) and how prostate cancer responds to two different doses of the investigational study drug (ARV-766) in men with metastatic cancer of the prostate who have progressed on prior approved systemic therapies for disease like yours (one of which must be enzalutamide, darolutamide, apalutamide or abiraterone).

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have a disease, called light chain (AL) amyloidosis, in which protein builds up through your body. The purpose of the study is to evaluate the safety and tolerability of venetoclax, MLN9708 (ixazomib citrate), and dexamethasone when used in combination for patients who have been previously treated for this disease but did not respond or have progressed. The study will test different doses of the drug to see which dose is safer for people.

The UVA Center for Leading Edge Addiction Research or CLEAR clinic is seeking men and women ages 18 and older to participate in a research study. The purpose of the study is to determine the safety, efficacy, and tolerability of low-intensity focused ultrasound on the brain of individuals with a diagnosis of cocaine use disorder. This study is for individuals who use cocaine and are not currently seeking treatment to stop.
The trial involves 5 in-person visits and 2 follow-up phone calls over a 10-week period. All study-related exams and tests are given at no cost.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with locally advanced or metastatic solid tumor to participate in a research study. The purpose of the study is to evaluate the investigational drugs MGC018 and MGD019 at different dose levels, and identify which dose of MGC018 in combination with MGD019 is the best dose that subjects can receive while trying to minimize severe symptoms, as well as looking at whether the investigational drugs cause your tumor to shrink or grow more slowly.

The COVID Clinical Trials team seeks adults with chronic kidney disease on or off dialysis for a research study. The purpose of the study is to test the safety or an oral medication to treat COVID-19.

The Gastroenterology Department seeks adults ages 18-65 who have been diagnosed with moderately to severe Crohn’s Disease of >3 months duration, to test if a combination of two market-approved medications are safe and effective for the treatment of CD.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have
microsatellite stable (MSS) Metastatic Colorectal Cancer and are starting, or have recently started, first-line
therapy. The purpose of this clinical research study is to learn more about an experimental therapeutic vaccine
that is “patient-specific”, meaning the vaccine each patient receives is developed specifically for them based on

The Adult Neurology’s Parkinson’s Disease and Movement Disorders Division seeks adults ages 40 to 75 with Parkinson’s Disease for a research study. The purpose of the study is see if an experimental drug (UCB0599) slows down disease progression over 12 to 18 months.

You may be eligible for this study if: you’ve been diagnosed with PD within the last 2 years and you have never taken medication to treat the motor symptoms of PD.